Clinical significance of peripheral blood CD4+ T cell subpopulations for immune checkpoint inhibitor treatment
Not Applicable
Recruiting
- Conditions
- Patients with gastrointestinal, hepatobilial, urological, or otorhinolaryngological cancer treated with an immune chekpoint inhibitor
- Registration Number
- JPRN-UMIN000041803
- Lead Sponsor
- Osaka General Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
patients with past history of an immune checkpoint inhibitor
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method